292. Ceftolozane/tazobactam for treatment of osteomyelitis due to multi-drug resistant Pseudomonas aeruginosa
Session: Poster Abstract Session: Bone and Joint Infections
Thursday, October 4, 2018
Room: S Poster Hall
Posters
  • CT osteo poster ID week 2018 Final.pdf (362.0 kB)
  • Background: Ceftolozane/tazobactam (C/T) has potent activity against Pseudomonas aeruginosa (PA). Clinical data describing use of C/T for PA osteomyelitis are limited. Our purpose is to describe clinical and microbiologic outcomes of adult patients treated with C/T for multidrug-resistant (MDR-PA) osteomyelitis.

    Methods: This was a retrospective study of hospitalized patients who received C/T ≥48 hours for MDR-PA osteomyelitis between 6/2015 and 7/2017. MDR-PA was defined as resistance to ≥1 antibiotic from ≥3 antibiotic classes. Osteomyelitis was diagnosed by imaging, presence of systemic inflammatory signs and symptoms, elevated C-reactive protein, and positive culture for MDR-PA. Combination antibiotic therapy was defined as systemic antibiotics susceptible to MDR-PA for ≥48 hours with C/T. Clinical cure was defined as complete or partial resolution of signs and symptoms of infection without need for escalation of antimicrobials during inpatient and outpatient therapy. Microbiological success is defined as eradication of MDR-PA in follow-up bone cultures. Descriptive statistics were used and presented at percent or median [Interquartile range].

    Results: 18 patients met inclusion and 4 patients were lost to follow-up. Demographics were male (81.2%), age 58.5 [53.5-68.5] years, 61.1% admitted to ICU, Charlson Comorbidity Index 5.5 [4-8] and APACHE II score 13.5 [11-21]. Site of osteomyelitis was pelvic in 55.6%, sacral in 22.2% and other sites in 22.2%. Surgical debridement occurred in 22.2%, and osteomyelitis was polymicrobial in 77.8%. Duration of hospitalization was 23.5 [12-37] days and all cause in-patient mortality was 16.7%. Median mean inhibitory concentration of C/T was 2 [2-4] mcg/mL. Median total duration of C/T was 42 [27-42] days. Combination antibiotics were used in 27.8% (16.7% polymyxins, 11.1% aminoglycosides, 5.6% ciprofloxacin) and 2 patients on polymyxins developed renal insufficiency. No patient developed hypersensitivity, neurologic events or C. difficile infections. Overall, clinical cure was 64.3% and 4 patients had repeat cultures with 75% achieving a microbiologic cure.

    Conclusion: These preliminary data suggest C/T maybe an option for treating patients with MDR-PA osteomyelitis, but more data are needed.

    Anthony Gerlach, PharmD, FCCM, FCCP, Pharmacy, The Ohio State University Wexner Medical Center, Columbus, OH and Jose Bazan, D.O., The Ohio State University College of Medicine, Columbus, OH

    Disclosures:

    A. Gerlach, Merck: Grant Investigator , Grant recipient .

    J. Bazan, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.